Protection of Rosuvastatin combined with Diltiazem in patients with AMI undergoing percutaneous coronary intervention

doi:10.3969/j.issn.1674-490X.2016.03.001

Abstract

Abstract: Objective To discuss the myocardial protection of Rosuvastatin combined with Diltiazem in patients undergoing percutaneous coronary intervention(PCI).Methods 150 patients with acute myocardial infarction(AMI)undergoing PCI were divided into group A(n=72)and group B(n=78).Both groups received high-dose rosuvastatin befor PCI and diltiazem by injecting intrainfarct-related artery,group A received diltiazem through continuous intravenous infusion additionally.The biochemical indexes,Thrombolysis In Myocardial Infarction(TIMI)and ST segment drop rate after 90 minutes were counted.Results Compared with the group B,the bochemical indexes decreased and rate of TIMI3,ST segment drop rate after 90 minutes increased obviously in group A.Conclusion High-dose rosuvastatin combined with diltiazem injection intrainfarct-related artery and intravenous infusion can protect myocardial.

Key words: acute myocardial infarction, Rosuvastatin, Diltiazem, percutaneous coronary intervention

CLC Number:

R541

ZHANG Lanfang,JIA Xinwei,WANG Zhanqi,XIE Junmin,HAN Kunpeng. Protection of Rosuvastatin combined with Diltiazem in patients with AMI undergoing percutaneous coronary intervention[J]. Medical Reserch and Education, 2016, 33(3): 1-5.

References

[1] 刘汉超.急诊PCI治疗ST段抬高急性心肌梗死的临床效果观察[J].中外医学研究,2015,13(36): 15-16.DOI: 10.14033/j.cnki.cfmr.2015.36.006
[2] HARRISON R W,AGGARWAL A,OU F S,et al.Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction[J].Am J Cardiol,2013,111(2): 178-184.DOI:10.1016/j.amjcard.2012.09.015.
[3] SCHWARTZ B G,KLONER R A.Coronary no reflow[J].J Mol Cell Cardiol,2012,52(4): 873-882.
[4] 刘倩梅,耿巍,张旗.急性心肌梗死急诊经皮冠状动脉介入治疗后无复流现象的危险因素分析[J].中国综合临床,2015,31(6):481-484.DOI: 10.3760/cma.j.issn.1008-6315.2015.06.001.
[5] 陈健.冠脉介入治疗术中无复流处理的研究进展[J].医学信息,2015(25): 383.DOI:10.3969/j.issn.1006-1959.2015.25.570.
[6] 席连东,刘亚娟.冠状动脉慢血流现象相关危险因素的探讨[J].中西医结合心脑血管病杂志,2015,13(2): 230-232.DOI:10.3969/j.issn.1672-1349.2015.02.036.
[7] 高玉龙,陶英,李志忠.心肌梗死溶栓试验危险评分对急性心肌梗死患者预后的评估价值[J].中国全科医学,2014,17(22): 2599-2602.DOI: 10.3969/j.issn.1007-9572.2014.19.015.
[8] 陈垚志,全南虎,麻鹏磊,等.介入术后无复流现象相关研究[J].中国老年学杂志,2015,35(5): 1427-1429.DOI: 10.3969/j.issn.1005-9202.2015.05.134.
[9] ITO D,SHIRAISHI J,NAKAMURA T,et al.Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy[J].Heart Vessels,2012,27(6):634-638.DOI: 10.1007/s00380-011-0222-5.
[10] 付文波,丁世芳,陈志楠,等.强化阿托伐他汀对急性心肌梗死急诊介入治疗中无复流的影响[J].中西医结合心脑血管病杂志,2015,13(1): 39-41.DOI: 10.3969/j.issn.1672-1349.2015.01.014.
[11] 郭华,陈炅,索冬卫.瑞舒伐他汀对冠心病患者心功能、血脂水平、血液流变学水平及内皮功能的影响[J].中国生化药物杂志,2015,35(5): 98-100.
[12] 路妍.瑞舒伐他汀对急性心肌梗死患者行择期PCI术的心肌保护作用[J].河北医药,2015,31(22):3434-3436.DOI: 10.3969/j.issn.1002-7386.2015.22.025.
[13] 史东,韩丽,张峰,等.直接PCI中早期经冠脉给予地尔硫卓预防无复流的效果[J].实用医学杂志,2014,30(23): 3832-3834.DOI:10.3969/j.issn.1006-5725.2014.23.043.
[14] 刘俊芳,连建学,李昌俊,等.地尔硫卓对动脉粥样硬化家兔血清C反应蛋白、白细胞介素-6水平的影响[J].中国医院药学杂志,2012,32(1):11-14.